Immunwork

Immunwork, Inc. is a privately held biotech company focusing on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel T-E drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on multi-arm linkers and various drug bundles. These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward...